1-6 of 6
Edward R. Scheffer Cliff
Close
Sort by
Journal Articles

Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

Clinical Trials & Observations
David A. Russler-Germain, Edward R. Scheffer Cliff, Nancy L. Bartlett
Journal: Blood
Blood (2023) 142 (25): 2216–2219.
https://doi.org/10.1182/blood.2023022048
Published: 2023
Journal Articles

Assessing the Impact of Blood Cancer Talks , a Novel ‘how I Treat’ Style Podcast on Hematologic Malignancies: A Survey-Based Analysis

Rajshekhar Chakraborty, Edward R Scheffer Cliff, Ashwin Kishtagari
Journal: Blood
Blood (2023) 142 (Supplement 1): 7270.
https://doi.org/10.1182/blood-2023-184594
Published: 2023
Journal Articles

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

George Mellgard, Molly Gilligan, Edward R Scheffer Cliff, Divaya Bhutani, Ghulam Rehman Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty
Journal: Blood
Blood (2023) 142 (Supplement 1): 4768.
https://doi.org/10.1182/blood-2023-174908
Published: 2023
Journal Articles

Trends in Medicare Spending on Multiple Myeloma Drugs, 2013 to 2021

Edward R Scheffer Cliff, Mark McGuire, Ghulam Rehman Mohyuddin, Aaron Seth Kesselheim, William B Feldman
Journal: Blood
Blood (2023) 142 (Supplement 1): 5086.
https://doi.org/10.1182/blood-2023-190372
Published: 2023
Journal Articles

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Joshua White, Sara Zhukovsky, Edward R Scheffer Cliff, Rajshekhar Chakraborty, Luciano Costa, Oliver Van Oekelen, Doug Sborov, Ghulam Rehman Mohyuddin
Journal: Blood
Blood (2023) 142 (Supplement 1): 2402.
https://doi.org/10.1182/blood-2023-185175
Published: 2023
Journal Articles

Pola-R-CHP for DLBCL: cost-effective at first glance

Edward R. Scheffer Cliff, Ankur Pandya
Journal: Blood
Blood (2022) 140 (25): 2654–2655.
https://doi.org/10.1182/blood.2022017342
Published: 2022